NCT04024800: An ongoing trial by NuGenerex Immuno-Oncology
This trial is ongoing. It must report results 1 month, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04024800 |
|---|---|
| Title | A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 3, 2019 |
| Completion date | June 30, 2023 |
| Required reporting date | June 29, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |